Multiple Myeloma Articles

FDA Places Holds on Several Durvalumab Combination Trials
The FDA has placed clinical holds on multiple trials in Celgene’s FUSION program, which is exploring regimens combining the PD-L1 inhibitor durvalumab with immunomodulatory and chemotherapy agents across several hematologic malignancies.
FDA Halts Enrollment on 3 Nivolumab Myeloma Trials
The FDA has placed partial clinical holds on 3 trials assessing nivolumab (Opdivo)-based combinations in patients with relapsed/refractory multiple myeloma.
Experts Discuss Strategies for Boosting Frontline Responses in Myeloma
During the past decade, the treatment of multiple myeloma has significantly changed, enabling more patients to achieve deep and durable responses.
The FDA released a statement today providing specific data from 2 phase III trials of pembrolizumab in multiple myeloma that the agency placed clinical holds on in July.
FDA Accepts sNDA for Carfilzomib Label Update in Myeloma
The FDA has accepted a supplemental new drug application seeking to add overall survival data from the phase III ENDEAVOR trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma.
Published Data Demonstrate Efficacy of Carfilzomib in Myeloma
Results from the phase III ENDEAVOR trial showed that carfilzomib (Kyprolis) reduced the risk of death by 21% compared with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma
Kumar Discusses Latest Developments in Myeloma
Shaji Kumar, MD, discusses his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of myeloma.
Expert Discusses Rapid Advances, Next Steps in Multiple Myeloma
Peter Voorhees, MD, discusses treatments for both newly diagnosed and relapsed patients with multiple myeloma.
XPO1 Inhibitor Offers Novel Mechanism for Treating Penta-Refractory Myeloma
Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.
Saad Z. Usmani, MD, discusses recent multiple myeloma data, the potential role of CAR T-cell therapy, and what therapeutic advancements the community can expect in the remainder of 2017.
Publication Bottom Border
Border Publication